References

Ali S, Mouton CP, Jabeen S, et al. Early detection of illicit drug use in teenagers. *Innov Clin Neurosci.* 2011;8(12):24-28.

American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics.* 2011*;*128(4):1007–1022. doi:10.1542/peds.2011-2654.

American Psychiatric Association (APA). *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington, VA: APA; 2013.

Berg CJ, Stratton E, Schauer GL, et al. Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win. *Subst Use Misuse*. 2015;50(1):79-89. doi:10.3109/10826084.2014.958857.

Bukstein OG, Bernet W, Arnold V, et al. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. *J Am Acad Child Adolesc Psychiatry.* 2005;44:609-621.

Bunnell RE, Agaku IT, Arrazola RA, et al. Intentions to smoke cigarettes among never-smoking US middle and high school electronic cigarette users: national youth tobacco survey, 2011-2013. *Nicotine Tob Res*. 2015;17(2):228-235. doi:10.1093/ntr/ntu166.

Carney T, Myers B. Effectiveness of early interventions for substance-using adolescents: findings from a systematic review and meta-analysis. *Subst Abus Treatment, Prev, Policy.* 2012;7(25). doi:10.1186/1747-597X-7-25.

Chan YF, Dennis ML, Funk RR. Prevalence and comorbidity co-occurrence of major internalizing and externalizing disorders among adolescents and adults presenting to substance abuse treatment. *J Subst Abuse Treat*. 2008;34:14-24.

Fiore MC, Jaen CR, Baker TB, et al. *Treating Tobacco Use and Dependence: 2008 Update*. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008. [http://bphc.hrsa.gov/buckets/treatingtobacco.pdf. Accessed October 13](http://bphc.hrsa.gov/buckets/treatingtobacco.pdf.%20Accessed%20October%2013), 2016.

Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. *Addiction.* 2010;105(9):1669-1676.

Food and Drug Administration (FDA). *FDA Announces Enhanced Warnings for Immediate-Release Opioid Pain Medications Related to Risks of Misuse, Abuse, Addiction, Overdose and Death*. Silver Spring, MD: FDA; 2016. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm>. Accessed August 11, 2016.

Griswold KS, Aronoff H, Kernan JB, Kahn LS. Adolescent substance use and abuse: recognition and management*. Am Fam Physician.* 2008;77(3):331-336.

Harris SK, Csémy L, Sherritt L, et al. Computer-facilitated substance use screening and brief advice for teens in primary care: an international trial. *Pediatrics.* 2012;129(6):1072-1082.

Harstad E, Levy S. Attention-deficit/hyperactivity disorder and substance use. *Pediatrics*. 2014;134(1):e293-e301. doi:10.1542/peds.2014-0992.

Hogue A, Liddle HA. Family-based treatment for adolescent substance abuse: controlled trials and new horizons in services research. *J Fam Ther*. 2009;31(2):126-154. doi:10.1111/j.1467-6427.2009.00459.x.

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* 2015;9:1-10. doi:10.1097/ADM.0000000000000166.

Karpinski JP, Timpe EM, Lubsch L. Smoking cessation treatment for adolescents. *J Pediatr Pharmacol Ther*. 2010;15(4):249-263. doi:10.5863/1551-6776-15.4.249.

LaBotz M, Griesemer BA, AAP Council on Sports Medicine and Fitness. Use of performance-enhancing substances. *Pediatrics*. 2016;138(1):e20161300. doi:10.1542/peds.2016-1300.

Levy S, Shrier, L, Massachusetts Child Psychiatry Access Project. *Adolescent SBIRT: Toolkit for Providers.* Boston, MA: Boston Children’s Hospital; 2015. <https://www.mcpap.com/pdf/S2BI%20Toolkit.pdf>. Accessed June 22, 2016.

Levy S, Williams J, Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. *Pediatrics*. 2016;138(1):e1-e15. doi:10.1542/peds.2016-1211.

Levy S, Winters KC, Knight JR. Screening and brief interventions for adolescent substance abuse in the general office setting. In: Kaminer Y, Winters KC, eds. *Clinical Manual of Adolescent Substance Abuse Treatment.* Washington, DC: American Psychiatric Publishing; 2010:65-81.

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev.* 2009:3:CD002209. doi:10.1002/14651858

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev*. 2008:2:CD002207. doi:10.1002/14651858.

Miller WR, Rollnick S. *Motivational Interviewing: Helping People Change.* 3rd ed. New York, NY: Guilford Press; 2012.

National Institute on Alcohol Abuse and Alcoholism (NIAAA). *Alcohol Screening and Brief Intervention for Youth: A Practitioner’s Guide.* NIH Publication No. 11-7805. Bethesda, MD: NIAAA; 2015. <http://pubs.niaaa.nih.gov/publications/Practitioner/YouthGuide/YouthGuide.pdf>. Accessed June 22, 2016.

National Institute on Alcohol Abuse and Alcoholism (NIAAA). *Underage Drinking*. Bethesda, MD: NIAAA; n.d. <http://www.niaaa.nih.gov/alcohol-health/special-populations-co-occurring-disorders/underage-drinking>. Accessed June 22, 2016.

National Institute on Drug Abuse (NIDA). *Principles of Adolescent Substance Use Disorder Treatment: A Research-Based Guide*. NIH Pub. No. 14-7953. Bethesda, MD: NIDA; 2014. <https://teens.drugabuse.gov/sites/default/files/podata_1_17_14_0.pdf>. Accessed June 22, 2016.

Pbert L, Moolchan ET, Muramoto M, et al. The state of office-based intervention for youth tobacco use. *Pediatrics*. 2003;111(6):e650-e660.

Pitts S, Shrier LA. Substance abuse screening and brief intervention for adolescents in primary care. *Pediatr Ann.* 2014;43(10):e248–e252.

Subramaniam GA, Fishman MJ, Woody G. Treatment of opioid-dependent adolescents and young adults with buprenorphine. *Current Psychiatry Reports*. 2009;11(5):360-363.

Subramaniam GA, Levy S. *Providers’ Clinical Support System for Medication Assisted Treatment: PCSS Guidance Treatment of Opioid-Dependent Adolescents and Young Adults Using Sublingual Buprenorphine.* Rev. ed.; 2013. <http://pcssmat.org/wp-content/uploads/2014/03/PCSS-MATGuidanceTreatmentofOpioidDependantAdolescent-buprenorphine.SubramaniamLevy1.pdf>. Accessed June 21, 2016.

Substance Abuse and Mental Health Services Administration (SAMHSA; a). *Certification of Opioid Treatment Programs (OTPs).* Rockville, MD: SAMHSA; 2015. <http://www.samhsa.gov/medication-assisted-treatment/opioid-treatment-programs>. Accessed September 2, 2016.

Substance Abuse and Mental Health Services Administration (SAMHSA; b). *Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide*. Rockville, MD: SAMHSA; 2015. <http://store.samhsa.gov/shin/content//SMA14-4892R/SMA14-4892R.pdf>. Accessed September 2, 2016.

Veliz P, Boyd C, McCabe SE. Adolescent athletic participation and nonmedical Adderall use: an exploratory analysis of a performance-enhancing drug. *J Stud Alcohol Drugs*. 2013;74(5):714-719. doi:10.15288/jsad.2013.74.714.

Wu P, Goodwin RD, Fuller C, et al. The relationship between anxiety disorders and substance use among adolescents in the community: specificity and gender differences. *J Youth Adolesc*.2010;39(2):177-188.